TrialCancer research communications2025

Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.

Kristoffer Staal Rohrberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.